Skip to main content
. 2022 Mar 21:10.2217/imt-2022-0027. doi: 10.2217/imt-2022-0027

Table 2. Concurrent therapies individuals received during nimotuzumab treatment.

Concurrent therapy Severe Moderate Total
n % n % n %
Recombinant IFN-α 0 0 3 30 3 7.3
Low-molecular-weight heparin 30 96.8 4 40 34 82.9
Steroids 28 90.3 3 30 31 75.6
Antibiotics 30 96.8 10 100 40 97.6
CIGB-258 12 38.7 1 10 13 31.7